[Special Stock] Cellid Secures Vaccine Sovereignty with Large-Scale Production of COVID-19 Preventive Vaccine under National Project with LG Chem

[Asia Economy Reporter Hyungsoo Park] Cellid's stock price is soaring. The news that it signed a memorandum of understanding (MOU) with LG Chem to establish a cooperative system for the development and production of a COVID-19 vaccine and to promote commercialization appears to have influenced the stock price.

As of 12:32 PM on the 5th, Cellid is trading at 46,700 KRW, up 19.74% from the previous trading day.

Cellid signed an agreement with LG Chem to establish a cooperative system for the development and mass production of the COVID-19 vaccine 'AdCLD-Cov19' under development and to promote its commercialization.

Earlier, Cellid began the development of the 'AdCLD-Cov19' vaccine in April. It produced a research-use 'AdCLD-Cov19' vaccine candidate. In primate trials, it confirmed remarkable antigen-specific antibody responses and a high level of virus neutralization ability of the generated antibodies.

In August, it was selected as the lead institution by applying for the 2020 4th Bio Medical Technology Development Project supported by the Ministry of Science and ICT, under the project for the development of original technologies to respond to new and mutant viruses.

Cellid plans to develop a COVID-19 preventive vaccine candidate based on an adenovirus vector and advance it to clinical trials, continuously developing original technologies to respond to new and mutant viruses, and secure preventive vaccine candidates against recently emerging COVID-19 variants.

Kang Chang-yul, CEO of Cellid, emphasized, "We expect rapid vaccine commercialization through the development of mass production processes and product manufacturing of the COVID-19 vaccine," adding, "This will alleviate public inconvenience, enable normal social activities, and contribute to revitalizing the national economy and industry that have been depressed."

The adenovirus vector-based vaccine developed by Cellid can induce a high level of antibody response with a single dose and also induce virus-specific T cell memory immune responses. It is highly valued for its economic efficiency, efficacy, and ease of administration, attracting significant attention. Considering that multinational pharmaceutical companies such as AstraZeneca and Johnson & Johnson, as well as China's CanSino, are clinically developing replication-defective adenovirus vector-based COVID vaccines, the company explained that the fact that a domestic pharmaceutical company is developing an adenovirus-based COVID vaccine holds important significance in terms of vaccine sovereignty.

This content was produced with the assistance of AI translation services.